Wall Street analyst estimates for aTyr Pharma, Inc. (ATYR): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 7 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.30 |
Valuation Ratios
| Price / Book | 0.72 |
| EV / EBITDA | -1.02 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $422000 | $10.5M | 0 | $10.4M | $353000 | $235000 | $190000 |
| Cost of Revenue | $900000 | $713000 | $746000 | $14.0M | $17.3M | $1.3M | $1.7M | 0 | 0 | $1.6M |
| Gross Profit | -$900000 | -$713000 | -$746000 | -$13.6M | -$6.8M | -$1.3M | $8.7M | $353000 | $235000 | -$1.4M |
| Research & Development | $44.2M | $30.1M | $20.4M | $14.0M | $17.3M | $23.3M | $42.8M | $42.3M | $54.4M | $60.2M |
| Selling, General & Admin | $14.2M | $16.4M | $11.7M | $9.4M | $9.1M | $10.8M | $12.3M | $13.0M | $13.8M | $17.6M |
| Operating Expenses | $58.4M | $46.4M | $32.1M | $9.4M | $9.1M | $32.7M | $55.1M | $55.3M | $68.1M | $76.3M |
| Operating Income | -$59.3M | -$47.1M | -$32.8M | -$23.0M | -$15.9M | -$34.0M | -$46.4M | -$54.9M | -$67.9M | -$77.6M |
| EBITDA | -$57.0M | -$46.4M | -$32.1M | -$22.3M | -$14.6M | -$32.5M | -$43.6M | -$47.7M | -$62.5M | -$72.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$57.9M | -$48.2M | -$34.5M | -$23.8M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| Income Tax | -$49000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$57.9M | -$48.2M | -$34.5M | -$23.6M | -$16.2M | -$33.8M | -$45.3M | -$50.4M | -$64.0M | -$74.1M |
| EPS | $-34.20 | $-26.16 | $-16.13 | $-7.03 | $-1.77 | $-1.77 | $-1.60 | $-0.94 | $-0.86 | $-0.80 |
| EPS (Diluted) | $-34.20 | $-26.16 | $-16.13 | $-7.03 | $-1.77 | $-1.77 | $-1.60 | $-0.94 | $-0.86 | $-0.80 |
| Shares Outstanding (Diluted) | $1.7M | $1.8M | $2.1M | $3.4M | $9.2M | $19.1M | $28.4M | $53.6M | $74.3M | $93.0M |
Price
| Price | $0.38 |
| Market Cap | $38M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACRV · ALXO · CAMP · DTIL · HYFT · MGX · QNCX
Explore sector: Healthcare · Biotechnology
More sections of ATYR: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks